Supernus Pharmaceuticals, Inc. SUPN

SUPN Company Overview

Supernus Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on the development and commercialization of central nervous system (CNS) therapies. The company operates within the biopharmaceutical and neurology-focused pharmaceutical industries, targeting conditions such as attention-deficit/hyperactivity disorder (ADHD), epilepsy, and other neurological disorders. Supernus primarily generates revenue through branded prescription medications sold in the United States, with a strategy centered on differentiated formulations of established compounds.

The company’s core commercial products include Qelbree for ADHD and extended-release epilepsy treatments such as Trokendi XR and Oxtellar XR. Supernus is positioned around proprietary formulation technologies designed to improve dosing convenience, tolerability, and patient adherence. Founded in 2005, Supernus evolved from a development-stage company into a fully integrated commercial organization following the approvals and launches of its CNS products in the 2010s, expanding further through targeted acquisitions.